Skip to content
Review Open access

Beyond Conventional PDOs: Organoids for Tumorigenesis for Gut Cancer Modeling and Fast Clinical Decision

Sep 2026 · Gut Medicine · Vol 2, pp. 116-120 · 0 citations · 14 references

TL;DR

Insight is provided into the potential use of tumorigenesis models and their key metrics, drawing on advances in gut medicine, which hold promise for future early diagnosis and clinical decision‐making.

Abstract

Reproducing tumor biology in vivo using three‐dimensional organoids remains a debated topic in the cancer organoid field, despite the new FDA framework for evaluating cancer drugs with organoid models. Compared with patient‐derived organoids (PDOs), which offer a humanized model for testing cancer therapies, organoids derived from normal stem cells primarily focus on elucidating mechanisms of tumor development and early prevention. To date, studies modeling colon cancer have successfully identified suitable pathways for organoid‐based tumorigenesis. In this perspective review, we provide insights into the potential use of tumorigenesis models and their key metrics, drawing on advances in gut medicine. Overall, developing personalized tumorigenic organoid models holds promise for future early diagnosis and clinical decision‐making.

Read PDF

Similar papers

Review Open access Oct 2026

Patient‐Derived Organoids in Functional Precision Oncology: Tumor Modeling, Drug‐Response Prediction, and Clinical Translation

Patient‐derived organoids (PDOs) have emerged as an effective experimental platform for bridging the long‐standing gap between traditional in vitro cancer models and the biological complexity of actual tumors. These three‐dimensional cultures (3D), derived directly from patient tissues, preserve essential architectural...

Abdullah Jabri, Mohamed Alsharif, Abdulaziz Mhannayeh et al. · 0 citations
Review Sep 2026

hPSC models in cancer mechanisms and therapeutic discovery.

This review will synthesize emerging findings, define key technological and biological gaps, and outline future directions for integrating hPSC-based modeling into precision oncology and translational cancer research.

Chih-Wei Chu, Yen-Tzu Chang, Candise Tat et al. · 0 citations
Review Open access Sep 2026

Organoids and AI-integrated models in ovarian cancer research: the future of personalized therapy

Ovarian cancer (OC) is the deadliest gynecological malignancy which continues to impose a significant challenge in the field of oncology research due to its rapid metastasis, inter and intra-tumor heterogeneity, and treatment resistance. Personalized medicine for OC is still under development where patient-derived orga...

A. Nikam, Gyamcho Tshering Bhutia, Sinjini Sarkar · 0 citations
Review Open access Sep 2026

Patient-derived prostate cancer organoids: model development, therapeutic applications, and challenges for precision oncology

Prostate cancer ranks among the most prevalent male malignancies worldwide, with castration-resistant prostate cancer (CRPC) and drug resistance representing major clinical challenges. Conventional preclinical models fail to faithfully recapitulate tumor heterogeneity and the tumor microenvironment (TME). Patient-deriv...

Jing-Zhen Zhu, Sheng Wang, Fu-Rong Du et al. · 0 citations

A Tissue Explant Model for Colon Cancer.

J. Epiney, Stefano Gussago, Pénélope Saint-Amour et al. · 0 citations
Review Oct 2026

Translational applications and clinical utility of organoids in ovarian cancer: a systematic review

This systematic review synthesized data from 13 studies evaluating the feasibility, histological fidelity, and clinical concordance of ovarian cancer patient-derived organoids to suggest PDOs represent a robust platform for functional drug screening within a clinically actionable 21-day window.

Reem Alzahrani, Maha Ali Alghadmi · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.